ASH 2022

Conference Coverage

ASH: Iron Deficiency More Likely in Formula-Fed Preemies

More infants in formula-fed versus breastfed group developed iron deficiency, despite having higher mean total daily iron intake.

Odronextamab Appears Safe, Effective in Relapsed/Refractory Follicular Lymphoma

By

Andrea S. Blevins Primeau, PhD, MBA

Odronextamab has demonstrated safety and efficacy in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.

Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL

By

Andrea S. Blevins Primeau, PhD, MBA

Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.

Frontline Regimens for MM Are Similar Across the World; Later Lines of Treatment Vary

By

Leah Lawrence

Worldwide, bortezomib-based triplets are the most common frontline treatment for multiple myeloma, but regimens used in later lines vary.

PTCy Plus Tacrolimus and MMF “Should Be Standard” GVHD Prophylaxis in RIC PBSCT

By

Andrea S. Blevins Primeau, PhD, MBA

PTCy plus tacrolimus and MMF should be standard GVHD prophylaxis in adults who receive a well-matched PBSCT after RIC, according to researchers.

Long-Term Risk of ITP Higher in Patients With Persistent, Isolated Mild Thrombocytopenia

By

Vicki Moore, PhD

Researchers sought to assess the risk of progression to ITP or hematologic neoplasia in adults with persistent, isolated mild thrombocytopenia.

Genomic Biomarker and Socioenvironmental Experiences Linked in Transplant Recipients

By

Vicki Moore, PhD

Researchers sought to determine whether there was a link between socioenvironmental experiences and a particular immunoregulatory pattern in recipients of HCT.

Silent Cerebral Infarction May Be Common on MRI in Patients With Immune Thrombotic Thrombocytopenic Purpura

By

Jonathan Goodman, MPhil

Researchers sought to determine whether MRI could show evidence of brain infarction in patients with iTTP.

Low-Dose Lenalidomide Confirmed to Reduce Time to Transfusion Dependence in Lower-Risk MDS

By

Andrea S. Blevins Primeau, PhD, MBA

Researchers sought to determine whether low-dose lenalidomide would prolong time to transfusion dependence among patients with low-risk MDS.

Zanubrutinib Outperforms Ibrutinib in Relapsed/Refractory CLL/SLL

By

Andrea S. Blevins Primeau, PhD, MBA

Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.

Chronic Lymphocytic Leukemia Updates Presented at the 2022 ASH Annual Meeting

By

Victoria Forster, PhD

Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.

Emicizumab Is Safe and Effective in Infants With Severe Hemophilia A

By

Andrea S. Blevins Primeau, PhD, MBA

Researchers sought to determine whether emicizumab would be effective in treating infants with severe hemophilia A without factor VIII inhibitors.

Blinatumomab-Based Consolidation Deemed New Standard Care for Adults With MRD-Negative B-ALL

By

Andrea S. Blevins Primeau, PhD, MBA

Blinatumomab-based consolidation is a new standard of care for ALL patients with MRD negativity after induction and intensification, researchers say.

Myelodysplastic Syndromes Updates From the 2022 ASH Annual Meeting

By

Caleb Rans, PharmD

Results from the MEDALIST, ASCERTAIN, STIMULUS-MDS1, and SINTRA-REV trials may help inform the treatment of MDS.

Monoclonal Antibody Shows Promise for Treating MPNs in Preclinical Study

By

Lauren Dembeck, PhD

Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.

Salvage Chemotherapy Before Allo-HSCT Does Not Improve Outcomes in Rel/Ref AML

By

Lauren Dembeck, PhD

Salvage chemotherapy before allogeneic transplant does not improve outcomes in relapsed/refractory acute myeloid leukemia, a phase 3 study suggests.

Glofitamab Can Provide Lasting Remissions in Heavily Pretreated Large B-Cell Lymphoma

By

Jessica Nye, PhD

Progression is “uncommon” in patients with relapsed/refractory large B-cell lymphoma who are in complete remission at the end of glofitamab treatment.

Ponatinib Plus Blinatumomab May Reduce Need for HSCT in Ph+ ALL

By

Jen Smith

Combination ponatinib and blinatumomab produced durable responses in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in a phase 2 trial.

Rapcabtagene Autoleucel Shows Activity in Relapsed/Refractory DLBCL

By

Jessica Nye, PhD

Rapcabtagene autoleucel may elicit durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Pozelimab and Cemdisiran Combination May Be Effective in Paroxysmal Nocturnal Hemoglobinuria

By

Jonathan Goodman, MPhil

Researchers sought to determine whether combining pozelimab and cemdisiran would be an effective treatment for patients with PNH.